Tommasina Guglielmelli
Overview
Explore the profile of Tommasina Guglielmelli including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
31
Citations
964
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
DAgostino M, Larocca A, Offidani M, Liberati A, Gaidano G, Petrucci M, et al.
Blood Cancer J
. 2021 Apr;
11(4):73.
PMID: 33846296
No abstract available.
2.
Saltarella I, Morabito F, Giuliani N, Terragna C, Omede P, Palumbo A, et al.
J Hematol Oncol
. 2019 Jan;
12(1):4.
PMID: 30626425
Background: Several new drugs are approved for treatment of patients with multiple myeloma (MM), but no validated biomarkers are available for the prediction of a clinical outcome. We aimed to...
3.
DAgostino M, De Paoli L, Conticello C, Offidani M, Ria R, Petrucci M, et al.
Crit Rev Oncol Hematol
. 2018 Nov;
132:9-16.
PMID: 30447931
Background: Risk-adapted therapy is a common strategy in curable hematologic malignancies: standard-risk patients receive less intensive treatment, whereas high-risk patients require a more intensive approach. This model cannot be applied...
4.
Mina R, Petrucci M, Corradini P, Spada S, Patriarca F, Cerrato C, et al.
Clin Lymphoma Myeloma Leuk
. 2018 Jun;
18(8):533-540.
PMID: 29910180
Background: High-dose therapy with autologous stem cell transplantation (HDT-ASCT) and maintenance treatment with novel agents are the best options for patients with newly diagnosed multiple myeloma, increasing the rate of...
5.
Maintenance in myeloma patients achieving complete response after upfront therapy: a pooled analysis
Cerrato C, Di Raimondo F, De Paoli L, Spada S, Patriarca F, Crippa C, et al.
J Cancer Res Clin Oncol
. 2018 Apr;
144(7):1357-1366.
PMID: 29675792
Purpose: Maintenance demonstrated to improve survival in newly diagnosed multiple myeloma (NDMM) patients and the achievement of complete response (CR) is a strong predictor of survival. Nevertheless, the role of...
6.
Magarotto V, Bringhen S, Offidani M, Benevolo G, Patriarca F, Mina R, et al.
Blood
. 2016 Jan;
127(9):1102-8.
PMID: 26729895
Lenalidomide-dexamethasone improved outcome in newly diagnosed elderly multiple myeloma patients. We randomly assigned 662 patients who were age ≥65 years or transplantation-ineligible to receive induction with melphalan-prednisone-lenalidomide (MPR) or cyclophosphamide-prednisone-lenalidomide...
7.
Palumbo A, Gay F, Cavallo F, Di Raimondo F, Larocca A, Hardan I, et al.
J Clin Oncol
. 2015 Aug;
33(30):3459-66.
PMID: 26282661
Purpose: Continuous therapy (CT) prolongs progression-free survival 1 (PFS1; time from random assignment until the first progression or death), but chemotherapy-resistant relapse may negatively impact overall survival (OS). Progression-free survival...
8.
Guglielmelli T, Giugliano E, Brunetto V, Rapa I, Cappia S, Giorcelli J, et al.
Oncoscience
. 2015 Jun;
2(4):382-94.
PMID: 26097872
mTOR is a protein kinase that plays a central role in regulating critical cellular processes. We evaluated the activation and cellular localization of the mTOR pathway in multiple myeloma (MM)...
9.
Guglielmelli T, Palumbo A
Expert Rev Hematol
. 2015 Jan;
8(3):253-6.
PMID: 25582032
Multiple myeloma (MM) accounts for 1% of all cancers and 13% of all hematologic malignancies. Melphalan-prednisone plus melphalan-prednisone-thalidomide or melphalan-prednisone-bortezomib are considered the standards of care for newly diagnosed, transplant-ineligible...
10.
Palumbo A, Bringhen S, Larocca A, Rossi D, Di Raimondo F, Magarotto V, et al.
J Clin Oncol
. 2014 Jan;
32(7):634-40.
PMID: 24449241
Purpose: Bortezomib-melphalan-prednisone (VMP) has improved overall survival in multiple myeloma. This randomized trial compared VMP plus thalidomide (VMPT) induction followed by bortezomib-thalidomide maintenance (VMPT-VT) with VMP in patients with newly...